Because of the peptides' high cost and unclear safety profile, "Big Pharma has abandoned them, " says Georgetown University researcher Michael Zasloff.
It has demonstrated that it understands the technical challenges and seems better able to drill these ultra deep wells at lower cost and with a fine safety profile than the major oil companies can.